Wegovy for Weight Management: How Semaglutide Works, Benefits, and Side Effects

Wegovy has become one of the most widely discussed prescription medications for medical weight management. It contains semaglutide, an active ingredient that mimics the action of the naturally occurring hormone GLP-1 to help regulate appetite and feelings of fullness.

For many people, losing weight is not simply a matter of eating less or exercising more. Hormonal regulation, metabolic health, underlying medical conditions, and the biological mechanisms controlling hunger can all influence weight management outcomes.

So, how does Wegovy work? How much weight can someone expect to lose? Is it safe, and who may be eligible for treatment?

Wegovy is a prescription medication containing semaglutide, a GLP-1 receptor agonist that supports weight management by regulating appetite and satiety. It is prescribed for patients who meet specific medical criteria and is used alongside dietary changes, physical activity, and appropriate medical supervision.

What Is Wegovy?

Wegovy is a brand-name medication containing semaglutide, developed by Novo Nordisk for the treatment of obesity and certain weight-related medical conditions.

Semaglutide belongs to a class of medications known as GLP-1 receptor agonist. These medications activate receptors for glucagon-like peptide-1 (GLP-1), a hormone naturally released by the body, particularly after eating.

GLP-1 plays an important role in regulating hunger, satiety, and blood glucose levels.

Semaglutide is designed to have a longer duration of action than naturally occurring GLP-1.

Wegovy is widely known as a once-weekly subcutaneous injection. Available formulations and dosing regimens may differ depending on the country and regulatory approval.

To understand the hormone behind this treatment, read What Is GLP-1 and How Does It Work for Weight Management?.

How Does Wegovy Work for Weight Loss?

Wegovy does not directly dissolve fat cells or instantly increase fat burning.

Instead, semaglutide works primarily through biological pathways that regulate appetite, satiety, and energy intake.

1. Helps Reduce Hunger

Semaglutide activates GLP-1 receptors involved in appetite regulation, including pathways within the central nervous system.

This can help patients feel less hungry and make it easier to manage their food intake.

Some individuals also experience fewer urges to snack between meals.

2. Increases Feelings of Fullness

Wegovy can help patients feel satisfied after eating smaller portions.

As feelings of fullness increase, overall daily calorie intake may decrease.

A sustained reduction in energy intake is one of the primary mechanisms contributing to weight loss during treatment.

3. Slows Gastric Emptying

Semaglutide can slow gastric emptying, meaning food moves from the stomach into the small intestine more slowly.

This effect may contribute to feelings of fullness, particularly during certain stages of treatment.

However, the effect on gastric emptying can change with longer-term use. This mechanism is also associated with some gastrointestinal side effects, such as nausea, abdominal fullness, and vomiting.

4. Supports Blood Glucose Regulation

Semaglutide helps stimulate insulin secretion when blood glucose levels are elevated and can suppress glucagon secretion under certain conditions.

Although Wegovy is prescribed for specific weight management indications, this mechanism also explains semaglutide's effects on glucose metabolism.

In summary, Wegovy primarily supports weight loss by reducing hunger, increasing satiety, and helping patients decrease their overall calorie intake.

How Effective Is Wegovy for Weight Loss?

The effectiveness of semaglutide has been evaluated in several clinical trials, including the STEP (Semaglutide Treatment Effect in People with Obesity) research program.

One important study is the STEP 1 trial, published in The New England Journal of Medicine in 2021.

The study involved 1,961 adults with obesity or overweight and at least one weight-related condition, without diabetes.

Participants received either semaglutide 2.4 mg once weekly or placebo, both alongside lifestyle interventions.

STEP 1 Clinical Trial Results

After 68 weeks, the study reported the following outcomes:

Clinical outcome	Semaglutide 2,4 mg	Placebo
Average weight reduction	14,9%	2,4%
Participants achieving ≥5% weight loss	86,4%	31,5%
Participants achieving ≥10% weight loss	69,1%	12,0%
Participants achieving ≥15% weight loss	50,5%	4,9%

Source: Wilding et al., NEJM, 2021.

These results demonstrate that semaglutide can produce clinically meaningful weight loss in appropriately selected patients.

These results demonstrate that semaglutide can produce clinically meaningful weight loss in appropriately selected patients.

An average weight reduction of 14.9% does not mean every patient using Wegovy will achieve the same result.

Individual outcomes depend on medical history, dosage, treatment adherence, dietary habits, physical activity, and personal response.

Who Is a Suitable Candidate for Wegovy?

Wegovy is not intended for everyone who wants to lose weight.

For adults, commonly used eligibility criteria for certain weight management medications include:

• Obesity BMI ≥30 kg/m².
• Overweight: BMI of 27 kg/m² or higher with at least one weight-related medical condition, such as hypertension, dyslipidemia, or obstructive sleep apnea.

These criteria must be interpreted according to the product's approved indications in Indonesia and an individualized medical assessment.

In Asian populations, metabolic risks may occur at lower BMI levels than in some other populations. Therefore, BMI should not be the only factor considered.

Before recommending treatment, a physician may evaluate:

• Current body weight and BMI.
• Weight history and previous weight changes.
• Metabolic health and existing medical conditions.
• Current medications.
• History of pancreatic or gastrointestinal disorders.
• Previous weight management treatments.
• Individual goals and expectations.

Patients seeking to lose only a few kilograms for cosmetic reasons may not have a medical indication for Wegovy.

How Is Wegovy Administered?

The injectable form of Wegovy is administered subcutaneously, typically once a week.

Common injection sites include the abdomen, thigh, or upper arm, according to the product instructions.

To reduce gastrointestinal side effects, treatment generally begins at a lower dose and increases gradually.

With commonly used injectable Wegovy regimens, dose escalation takes place over several months before reaching an appropriate maintenance dose.

However, the exact dosage, titration schedule, and treatment regimen must follow the locally approved prescribing information and the physician's assessment.

Patients should not increase their dose independently in an attempt to accelerate weight loss.

Treatment should also be accompanied by appropriate nutritional management and physical activity.

How Long Does Wegovy Take to Work?

Some patients begin noticing changes in appetite and fullness during the first few weeks of treatment.

However, clinically meaningful changes in body weight are generally evaluated over several weeks to months.

In the STEP 1 trial, weight reduction developed progressively throughout the treatment period.

The study's primary results were assessed at week 68, meaning these outcomes should not be interpreted as expected results within the first few weeks.

Because Wegovy is generally introduced through gradual dose escalation, treatment progress should be evaluated according to the current treatment stage, medication tolerability, and individual response.

Effective weight management should consider not only the number on the scale but also metabolic health, nutritional adequacy, and preservation of muscle mass.

What Are the Side Effects of Wegovy?

Like other prescription medications, Wegovy can cause side effects.

The most commonly reported side effects involve the gastrointestinal system, including:

• Mual.
• Vomiting
• Diarrhea
• Constipation.
• Abdominal pain or discomfort.
• Bloating or abdominal fullness.

These symptoms are particularly common when starting treatment or increasing the dosage.

More serious potential risks include acute pancreatitis, gallbladder disease, dehydration-related kidney injury, and severe allergic reactions.

The risk of hypoglycemia may increase when semaglutide is used alongside insulin or certain diabetes medications.

Certain medical histories may also require additional precautions or make treatment unsuitable.

For example, US prescribing information lists a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) as contraindications.

Wegovy should not be used for weight loss during pregnancy. Patients planning pregnancy should discuss discontinuing semaglutide with their physician. Certain prescribing information recommends stopping treatment at least two months before a planned pregnancy.

Patients experiencing persistent severe abdominal pain, prolonged vomiting, or symptoms of a severe allergic reaction should seek immediate medical attention.

Wegovy should only be used when medically indicated and under appropriate physician supervision.

Can You Regain Weight After Stopping Wegovy?

Yes. Weight regain can occur after semaglutide treatment is discontinued.

This is partly because appetite and body weight are regulated by long-term biological mechanisms.

In the STEP 1 trial extension, participants who stopped semaglutide regained approximately two-thirds of their previously lost weight during the following year.

These findings highlight the importance of a sustainable, long-term approach to weight management.

A weight maintenance strategy may include:

• Sustainable, balanced eating habits.
• Regular physical activity.
• Strength training to help preserve muscle mass.
• Adequate sleep.
• Monitoring of body weight and metabolic health.
• Ongoing medical evaluation when appropriate.

Treatment duration varies between individuals. Decisions about continuing or discontinuing Wegovy should be based on its benefits, potential risks, tolerability, and the patient's medical circumstances.

Wegovy vs Mounjaro: What Is the Difference?

Wegovy and Mounjaro are both frequently discussed in medical weight management, but they contain different active ingredients and work through different mechanisms.

Feature	Wegovy	Mounjaro
Active ingredient	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist
Appetite regulation	Yes	Yes
Weight management use	According to approved indications	According to approved indications
Medical supervision required	Yes	Yes

Tirzepatide activates both GIP and GLP-1 receptors, whereas semaglutide acts on GLP-1 receptors.

These differences can influence clinical outcomes, but choosing a medication involves more than comparing weight loss percentages.

A physician should consider medical history, approved indications, contraindications, tolerability, availability, and patient preferences.

For a more detailed comparison, read Wegovy vs Mounjaro for Weight Loss: What’s the Difference?.

You can also learn more in Mounjaro for Weight Loss: Understanding Tirzepatide.

Is Wegovy the Same as Fat-Dissolving Injections?

No. Wegovy and localized fat reduction treatments have different purposes and mechanisms of action.

Wegovy is a prescription medication that supports overall weight management by influencing appetite and energy intake.

Localized fat reduction treatments, on the other hand, are intended to address unwanted fat in specific areas of the body.

For example, someone may have a relatively stable body weight but still experience localized fat accumulation around the abdomen, arms, or double chin.

This does not necessarily mean they need GLP-1 medication.

Ovela Clinic offers several body contouring and localized fat treatment options, including Fat Loss Therapy, Meso Fat Apoptosis, and Radiofrequency Body Contouring

The most appropriate approach depends on the patient's condition, treatment goals, and the indications for each procedure.

Medical Weight Management Consultation at Ovela Clinic Jakarta

For patients considering Wegovy, semaglutide, or other GLP-1-based medications, a medical consultation is an important first step.

Through WeightMod Therapy at Ovela Clinic, patients can discuss a medically supervised approach to weight management tailored to their health conditions and treatment goals.

The WeightMod program focuses on medical assessment and physician supervision rather than medication alone.

An assessment may include evaluation of BMI, medical history, metabolic health, current medications, and factors influencing body weight.

When clinically appropriate, the physician may consider medication-based treatment, including GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, subject to approved indications and medication availability.

Ongoing monitoring helps evaluate treatment response, tolerability, potential side effects, and whether treatment adjustments are needed.

Frequently Asked Questions About Wegovy

1. What is Wegovy used for?

Wegovy is a prescription medication containing semaglutide, a GLP-1 receptor agonist used for certain medical indications, including chronic weight management in eligible patients.

2. Is Wegovy the same as Ozempic?

Wegovy and Ozempic both contain semaglutide, but they may have different approved indications, formulations, and dosing regimens. They should not automatically be considered interchangeable.

3. How often is Wegovy injected?

The commonly used injectable formulation of Wegovy is administered once weekly. The exact schedule and dose must follow the product instructions and physician's prescription.

4. Can you use Wegovy without having diabetes?

Yes. Wegovy has weight management indications for certain patients without diabetes, provided they meet the relevant medical eligibility criteria and locally approved indications.

5. How much weight can you lose with Wegovy?

Results vary. In the STEP 1 clinical trial, semaglutide 2.4 mg alongside lifestyle interventions produced an average weight reduction of approximately 14.9% after 68 weeks. This does not guarantee the same result for every patient.

6. Is Wegovy safe for long-term use?

Wegovy has been studied in long-term clinical trials. However, continued treatment requires individualized assessment, monitoring, and consideration of potential risks and benefits.

7. Will I regain weight after stopping Wegovy?

Weight regain is possible after discontinuing treatment. A long-term weight maintenance strategy is therefore an important part of medical weight management.

8. Where can I consult a doctor about Wegovy in Jakarta?

Patients considering Wegovy or other medical weight management options can arrange a consultation through WeightMod Therapy at Ovela Clinic Jakarta. Medication is considered only when medically appropriate and subject to applicable indications and availability.

Weight Management Is About More Than the Number on the Scale

Wegovy represents an important development in medical treatment for obesity and certain weight-related conditions.

However, not everyone needs or is suitable for semaglutide.

An appropriate weight management strategy should consider overall health, metabolic factors, treatment goals, and long-term weight maintenance.

If you are considering Wegovy, Mounjaro, or other medical weight loss treatments, a consultation can help determine which approach may be appropriate for your individual circumstances.

Explore WeightMod Therapy – Medical Weight Management at Ovela Clinic Jakarta.

Ovela Clinic Tebet – South Jakarta

WhatsApp: 0857-8888-9188

Ovela Clinic Kebon Jeruk – West Jakarta

WhatsApp: 0822-4040-8086

Book Your WeightMod Consultation

Medical References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Obesity and Metabolism. 2022;24:1553–1564. https://doi.org/10.1111/dom.14725
3. European Medicines Agency. Wegovy (semaglutide): Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy

Medical Disclaimer: This article is intended for educational purposes only and does not replace individualized medical advice. Prescription weight management medications should only be used according to approved indications and under appropriate medical supervision.